

1
2
3
4
5
6 Original article
7
8

9
10 A novel self-assembling peptide for hemostasis during endoscopic submucosal
11
12 dissection: a randomized controlled trial
13

14 Sharmila Subramaniam¹, Kesavan Kandiah^{1,2}, Fergus Chedgy^{1,3}, Carole Fogg^{4,5},
15
16 Sreedhari Thayalasekaran¹, Asma Alkandari¹, Michelle Baker-Moffatt¹,
17
18 Joanne Dash¹, Mark Lyons-Amos⁴, Gaius Longcroft-Wheaton^{1,6}, James Brown⁶,
19
20 Pradeep Bhandari^{1,6}
21
22

23
24 ¹ Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth Hospitals
25
26 NHS Trust, Portsmouth, UK
27
28

29
30 ² Department of Gastroenterology, St George's University Hospital NHS Trust,
31
32 London, UK
33

34
35 ³ Department of Gastroenterology, Brighton and Sussex University Hospitals NHS
36
37 Trust, Brighton and Hove, UK
38
39

40
41 ⁴ Department of Research and Innovation, Queen Alexandra Hospital, Portsmouth
42
43 Hospitals NHS Trust, Portsmouth, UK
44

45
46 ⁵ School of Health Sciences, University of Southampton, Southampton, UK
47

48
49 ⁶ School of Pharmacy and Biomedical Sciences, University of Portsmouth,
50
51 Portsmouth, UK
52
53

54
55
56 Short title: Novel self-assembling peptide for hemostasis during ESD
57
58
59
60

1
2
3 Corresponding author
4

5
6 Pradeep Bhandari, MD
7

8
9 Department of Gastroenterology
10

11
12 Queen Alexandra Hospital
13

14
15 Portsmouth Hospitals NHS Trust
16

17
18 Southwick Hill Road, Cosham
19

20
21 PO6 3LY
22

23
24 UK
25

26
27 Email: pradeep.bhandari@porthosp.nhs.uk
28

29
30 or:
31

32
33 deep3570@yahoo.co.uk
34

35
36 Submitted: 29 October 2019 Accepted after revision: 6 May 2020
37

38
39 Copy editor: j.w. / 30 May 2020 / Typesetting deadline
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Background:** Endoscopic submucosal dissection (ESD) is associated with a risk of
4 bleeding. Bleeding is usually treated with diathermy, although this does carry a risk of
5 mucosal thermal injury. Purastat is a topical hemostat that may be effective in
6 controlling bleeding during ESD, thereby reducing the use of heat therapy. The aim of
7 this study was to assess the reduction in heat therapy used in the interventional group
8 (Purastat) compared with the control group. The secondary aims were to compare the
9 procedure length, time for hemostasis, delayed bleeding rate, adverse events, and
10 wound healing between the groups.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods:** This was a single-center randomized controlled trial of 101 patients
23 undergoing ESD. Participants were randomized to a control group where diathermy was
24 used to control bleeding or an interventional group where Purastat could be used.
25 Follow-up endoscopy was performed at 4 weeks to assess wound healing.
26
27
28
29
30
31

32 **Results:** There was a significant reduction in the use of heat therapy for intraprocedural
33 hemostasis in the interventional group compared with controls (49.3% vs. 99.6%,
34 $P < 0.001$). There were no significant differences in the procedure length, time for
35 hemostasis, and delayed bleeding rate between the groups. Complete wound healing at
36 4 weeks was noted in 48.8% of patients in the interventional group compared with
37 25.0% of controls ($P = 0.02$).
38
39
40
41
42
43
44
45

46 **Conclusions:** This study has demonstrated that Purastat is an effective hemostat that
47 can reduce the need for heat therapy for bleeding during ESD. It may also have a role
48 in improving post-resection wound healing.
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Endoscopic submucosal dissection (ESD) is an effective technique for removal of superficial gastrointestinal (GI) neoplasia. However, its uptake in the West has been hampered by concerns over a high complication rate and the lengthy learning curve. Intraprocedural bleeding (IPB) is a well recognized complication. The usual method of controlling IPB is with electrocautery that is applied through the tip of the knife or via hemostatic forceps [1,2]. Heat application may result in mucosal thermal injury that can lead to perforation. There is also a risk of post-ESD electrocoagulation syndrome (PEECS), which is associated with female patients, right-sided colonic lesions, and lesions of >4 cm in size [3].

Delayed bleeding is another risk associated with ESD, ranging from 1%–15% depending on lesion location, size, and anticoagulant use [4]. Prophylactic clipping following colonic endoscopic resection showed no benefit [5] and prophylactic coagulation of vessels over the resection base has only been shown to be effective in reducing delayed bleeding post-gastric ESD [6,7].

Recently, topical hemostats have emerged as alternative non-diathermic modalities to manage bleeding. These are supplied as opaque powders that can be sprayed over the bleeding point [8,9]. Purastat (3D-Matrix Europe Ltd., France) is a novel synthetic self-assembling peptide that is licensed for use as a hemostat. Its unique transparent gel formulation forms an extracellular scaffold matrix when activated by the change in pH that occurs upon contact with blood. This matrix forms a stable mechanical barrier over the bleeding site thereby facilitating intrinsic in vivo hemostasis.

Initial preclinical studies investigating this peptide have shown other benefits in addition to its hemostatic properties, including improved wound healing [10–14]. The first clinical trial of Purastat was conducted in vascular surgery, where it was used on

1
2
3 33 vascular anastomotic sites in 25 patients [15]. It has also had favorable outcomes in
4 nasal and cardiothoracic surgery [16,17]. Within endoscopy, its impact on delayed
5 bleeding and wound healing following ESD has shown promise [18,19]. Only one small
6 study of 12 gastric ESD patients has assessed its hemostatic efficacy – this showed it
7 was effective in 92% of cases [20]. Purastat has been shown to be safe with no device-
8 related adverse events reported. However, a major limitation of the evidence available
9 is that all the studies have lacked a control group for comparison. There are few data on
10 the efficacy of Purastat in controlling IPB during endoscopic resection. However, if it
11 could reduce the need for thermal hemostasis by controlling some of the bleeds
12 encountered, it would improve the safety profile of ESD.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The primary aim of the study was to assess the reduction in the use of heat for treatment of IPB during ESD when Purastat was used as a hemostat. The secondary aims were to compare the procedure length, time for hemostasis, delayed bleeding rate, adverse events, and wound healing in the interventional arm (Purastat) and control group.

Methods

Study design

This study was a single-center randomized controlled clinical trial involving patients who were undergoing esophageal and colonic ESD procedures only. It was registered at <http://www.clinicaltrials.gov> (identifier: NCT02833558) and approved by the South Central Hampshire A research ethics committee (reference: 16/SC/0020).

Study participants

Patients over 18 years of age scheduled for elective esophageal or colonic ESD for lesions of 2–5 cm were eligible for participation. Patients aged under 18 years, unable to provide informed consent, with submucosal tumors or lesions with deep submucosal

1
2
3 invasion, with an inherited or acquired coagulopathy likely to affect the risk of bleeding,
4
5 or receiving an anticoagulant therapy, except for aspirin, that could not be stopped or
6
7 bridged pre-procedure were excluded. All participants provided written informed
8
9 consent for the ESD procedure and separate consent for participation in the study.
10
11
12 Baseline demographic data were recorded.
13
14
15

16 *Randomization*

17
18 All patients recruited were randomized in a 1:1 fashion to either the control or
19
20 interventional arms. Each participant was allocated a unique trial reference number and
21
22 computer-generated randomization was carried out at the time of the ESD using a web-
23
24 based platform (<https://www.sealedenvelope.com/>).
25
26
27

28 *Blinding*

29
30 This was a single-blind study where patients were not informed about their
31
32 randomization allocation in order to increase reliability during follow-up. Owing to the
33
34 differences in the interventions, it was not possible to blind the endoscopist performing
35
36 ESD.
37
38
39

40 *Endoscopic technique and hemostatic intervention*

41 42 Endoscopic submucosal dissection

43
44
45 All esophageal ESD procedures were done with the patient under general anesthetic
46
47 with a planned overnight hospital stay. Colonic ESD procedures were performed as
48
49 day-cases with the patient under conscious sedation. Uninterrupted single antiplatelet
50
51 therapy with aspirin was permitted, while all other anticoagulants were discontinued
52
53 before the procedure as per national guidelines [21].
54
55
56
57
58
59
60

1
2
3 One endoscopist (P.B.; lifetime experience of over 500 ESD procedures) performed all
4 of the ESDs. Hybrid ESD was used in cases where significant submucosal fibrosis was
5 anticipated and this was decided on the basis of lesion assessment at the time of the
6 procedure prior to randomization.
7
8
9
10

11
12 A standard lifting solution (500 mL Gelofusine + 1 mL 1:10000 adrenaline + 1 mL 1%
13 indigo carmine) and the DualKnife or DualKnife J (Olympus Medical UK) were used
14 for all procedures. An Erbe VIO 300D electrosurgical generator (Erbe Medical,
15 Tübingen, Germany) was used for diathermy. Endocut I (effect 2, cut interval 3, cut
16 duration 3) was used for mucosal incision followed by submucosal dissection on swift
17 coagulation (effect 4, 50 W). The procedure length was measured in minutes as the time
18 taken from the point of submucosal injection to the end of dissection.
19
20
21
22
23
24
25
26
27
28
29

30 Hemostasis

31
32 The start and stop times for each episode of IPB were measured. The number of bleeds
33 that stopped spontaneously without treatment was recorded. We used the definitions
34 described in an earlier study to classify the bleeds into three grades (grade 1, mild
35 oozing; grade 2, moderate non-spurting bleeding with visible vessel; grade 3, arterial
36 spurting) [22].
37
38
39
40
41
42
43
44
45

46 Control arm

47
48 All patients allocated to the control group received electrocoagulation treatment for
49 IPB. This was applied either via the endoscopic knife tip (swift coagulation mode; effect
50 4, 50 W) or using a coagulation forceps (Coagrasper; Olympus Medical UK) on soft
51 coagulation mode (effect 4, 80 W). The Coagrasper was used in more severe bleeds.
52
53
54
55
56
57
58
59
60

1
2
3 Interventional arm
4

5
6 This was a pragmatic real-life study designed to incorporate the use of Purastat into the
7
8 treatment of IPB in the interventional arm without increasing the complexity of the
9
10 procedure. Purastat was used for grade 1 and 2 bleeds that were encountered outside
11
12 the immediate vicinity of the tip of the knife or when the bleeding point was not easily
13
14 accessible for diathermy (e.g. when the bleeding point was not clearly visible because
15
16 of blood pooling, was situated in the deeper planes or at the edge of an incision where
17
18 the bleeding vessel was not fully exposed, or where access to the lesion was unstable).
19

20
21
22 Purastat was applied via a bespoke catheter inserted through the endoscope accessory
23
24 channel (**Fig. 1**). The volume of Purastat used and the time to hemostasis was measured.
25
26 If a bleed was not controlled by either Purastat or diathermy, the endoscopist was
27
28 permitted to use other treatment modalities.
29

30
31
32 Our previous experience with Purastat demonstrated that it worked best in grade 1 and
33
34 2 bleeds, but not in grade 3 bleeds [22]. Therefore, the study protocol permitted the use
35
36 of diathermy with the endoscopic knife tip (in grade 1 & 2 bleeds) if the bleeding point
37
38 was clearly visible in the immediate vicinity of the knife and the Coagrasper in grade 3
39
40 spurting bleeds where Purastat was not recommended. This strategy addressed any
41
42 potential ethical dilemmas regarding the value of withdrawing the knife and inserting
43
44 the catheter for Purastat delivery when the knife could achieve safe hemostasis.
45
46

47
48 Purastat was applied over the resection base at the end of all procedures in the
49
50 interventional arm. No other treatment (prophylactic coagulation or clipping) was
51
52 carried out in either group. The ease of application was recorded and any issues
53
54 encountered (e.g. catheter blockage, interference with visibility or electrical
55
56 conductivity through the knife).
57
58
59
60

1
2
3 *Follow-up*
4

5 All patients undergoing esophageal ESD received high dose proton pump inhibitor
6 therapy (40 mg twice daily omeprazole or equivalent) for 8 weeks post-procedure. All
7 patients returned approximately 4 weeks post-procedure for a repeat endoscopy to
8 inspect the resection site. Complications or adverse events (delayed bleeding,
9 perforation, unexpected hospital admissions) related to the ESD were recorded at this
10 visit. Delayed bleeding was defined as overt hemorrhage occurring between 24 hours
11 and 30 days post-procedure and requiring medical intervention
12 (endoscopic/radiological/surgical management), with or without a blood transfusion.
13 Immediate/early rebleeding was defined as overt hemorrhage occurring within the first
14 24 hours post-procedure requiring intervention as above.
15
16
17
18
19
20
21
22
23
24
25
26
27

28 All follow-up endoscopies were carried out by two experienced endoscopy fellows who
29 were blinded to the patient's randomization. We adapted the wound healing categories
30 based on the Sakita and Fukutomi ulcer staging classification [23]. The categories used
31 were healing ulceration, scarring, and complete healing (**Fig. 2**).
32
33
34
35
36
37
38

39 *Outcomes*

40 The primary outcome was the mean reduction in intraprocedural heat therapy required
41 when Purastat was used for hemostasis in ESD.
42
43
44
45

46 Secondary outcomes measured were: total procedure length; time taken for hemostasis
47 using Purastat compared with diathermy; proportion of patients with complete wound
48 healing, scarring, and healing ulceration present at follow-up endoscopy; and
49 complication rates in the two arms.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Statistical methods and sample size calculation*
4

5 An intention-to-treat analysis was performed. Baseline characteristics were compared
6
7 using the independent *t* test for continuous variables (e.g. age and lesion size) and chi-
8
9 squared or Fisher's exact tests for categorical variables (e.g. sex, co-morbidities, anti-
10
11 thrombotic agents, en bloc resection, location, circumference, procedure type). Chi-
12
13 squared tests were also used to compare differences between the two arms in the
14
15 primary end point and the secondary end points (delayed bleeding, adverse events,
16
17 wound healing). *P* values obtained were two-sided and a *P* value of <0.05 was
18
19 considered significant in all cases. Statistical analyses were carried out using SPSS
20
21 version 24.
22
23
24
25

26 The sample size calculation utilized the *t* test for two independent samples and was
27
28 based on the primary outcome measure of reducing the number of episodes of IPB
29
30 requiring heat for hemostasis. As there is a lack of data on hemostasis in ESD, the
31
32 sample size calculation was based on assumptions derived from ESD expert experience.
33
34 We assumed that hemostasis would be required on average 10 times per patient (with a
35
36 standard deviation of 5). We hypothesized that Purastat would reduce the number of
37
38 episodes of IPB requiring heat treatment by 30%. To detect this difference with 80%
39
40 power (assuming a two-sided significance level of 5%), the study would require 45
41
42 patients in each trial arm (90 patients in total). The recruitment target was increased by
43
44 10% to 100 patients in order to account for study withdrawals. The sample size
45
46 calculation was performed using R for Windows (version 3.5.3).
47
48
49
50
51

52 **Results**

53 A total of 101 patients were recruited and randomized into the two groups from May
54
55 2016 to April 2018. There were three patients who were withdrawn from the study: two
56
57 had aborted ESD procedures and one had a lesion better suited for EMR so did not
58
59
60

1
2
3 proceed to ESD. There were five patients in the Purastat arm and two in the control arm
4 who did not have any IPB. Therefore, the intention-to-treat analysis was performed on
5 the remaining 91 patients (**Fig. 3**).
6
7
8
9

10 11 *Baseline patient and procedural characteristics*

12 There were no significant differences between the patient and lesion characteristics in
13 the two groups (**Table 1**). Notably, this was a high risk study population with a high
14 proportion of patients (50% in the Purastat group and 38% in the control group) having
15 significant co-morbidities, such as cardiorespiratory conditions, diabetes, or previous
16 cerebrovascular accident. About 40% of patients in each group had been on
17 anticoagulant therapy which was stopped before the procedure. The study protocol
18 permitted conversion from ESD to hybrid ESD (~10%) for reasons of technical
19 difficulty or if time/patient tolerance proved a constraint. A similar proportion of
20 patients (37% vs. 42%) underwent hybrid ESD, which is reflected in the low en bloc
21 resection rates.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 *Intraprocedural bleeding and primary outcome*

39 There were 269 bleeds in 45 patients in the control group and 232 bleeds in 46 patients
40 in the Purastat group. There was no significant difference in the proportion of bleeds
41 requiring treatment in the two groups (95.3% vs. 97.4%) or the mean number of bleeds
42 per patient (5.0 vs. 6.0) (**Table 2**). The majority of bleeds in both groups were grade 1
43 and 2 bleeds.
44
45
46
47
48
49
50

51 There was a 50% reduction in the number of episodes of IPB treated by diathermy in
52 the interventional arm. Diathermy was used for 109/221 bleeds requiring treatment
53 (49.3%) in the Purastat arm. In 100/109 bleeds, this was owing to the severity of the
54 bleed or the location being in the immediate vicinity of the knife tip, whereas 9/109
55
56
57
58
59
60

1
2
3 uses of diathermy were because of unsuccessful treatment with Purastat. There were
4
5 112 bleeds that were treated with Purastat as a primary hemostat and nine that were
6
7 treated following the application of diathermy. Purastat achieved complete hemostasis
8
9 in 92.6% of these bleeds (112/121).
10
11
12

13 14 *Secondary outcomes*

15 The mean length of time for hemostasis using Purastat was similar compared with
16
17 diathermy (70 vs. 78 seconds, $P = 0.14$) (**Table 3**). The total procedure time was also
18
19 similar (74 vs. 81 minutes for the interventional and control arms, respectively). Only
20
21 a small amount of Purastat was required (mean of 0.43 mL per bleed) for hemostasis
22
23 and for prophylactic coverage of the resection base (mean of 2.03 mL per patient).
24
25
26
27

28 29 *Delayed bleeding and adverse events*

30 There were two delayed bleeds in each arm (delayed bleeding rate 4.3% vs. 4.4%). All
31
32 bleeds were managed endoscopically and no further episodes of rebleeding occurred
33
34 post-endoscopy. There was one perforation in the interventional arm, which was
35
36 unrelated to the application of Purastat and attributed to the lesion histology
37
38 (submucosally invasive cancer).
39
40
41
42

43 44 *Technical feasibility*

45 Purastat was rated as easy to apply with complete coverage of the resection base
46
47 achieved in the interventional arm. It was reported to “interfere with visibility” in two
48
49 patients: both had multiple sites of IPB within close proximity necessitating repeated
50
51 applications of the gel in the same field of resection.
52
53
54

55 56 *Wound healing*

57 The median length of follow-up was 30 days in both groups. There was a significant
58
59 increase in the proportion of patients achieving complete wound healing in the Purastat
60

1
2
3 group compared with controls (48.8% vs. 25.0%, $P = 0.02$) (**Table 4**). However, in a
4
5 subgroup analysis according to location, no significant difference between the groups
6
7 was noted in wound healing post-esophageal ESD (**Table 5**). This was in contrast to
8
9 colorectal ESD, where a higher proportion of patients in the control group were noted
10
11 to have ulceration over the resection site during follow-up endoscopy (56% vs. 17.6%,
12
13 $P = 0.01$), indicative of incomplete wound healing.
14
15
16
17

18 **Discussion**

19
20 Bleeding is a well recognized complication of ESD. IPB can prolong the procedure
21
22 time, increase the risk or complexity of the ESD, and compromise the dissection planes.
23
24 Delayed bleeding can lead to additional length of stay and increases the morbidity
25
26 associated with the procedure. Thus far, conventional treatment of IPB has been carried
27
28 out using diathermy, which can increase the risk of thermal injury. Our study
29
30 investigated the use of a novel hemostat to tackle procedure-related bleeding, with the
31
32 aim of reducing the amount of heat therapy required.
33
34
35

36
37 We demonstrated that Purastat is a safe and viable hemostat for mild to moderate IPB
38
39 during ESD and led to a significant reduction in the use of diathermy for hemostasis.
40
41 This is the first randomized controlled study using this hemostat and both groups of
42
43 patients were well matched in terms of their risk factors for bleeding. There was only
44
45 limited conversion from ESD to hybrid ESD, which did not have a significant effect on
46
47 the primary end point, given the ratio of conventional to hybrid procedures was similar
48
49 in the two arms.
50
51

52
53 There is limited literature available on the amount of energy needed to cause a full-
54
55 thickness perforation; however, it is widely accepted that any use of monopolar
56
57 electrocoagulation current on an ESD base carries the risk of thermal injury and can
58
59
60

1
2
3 lead to PEECS. The incidence of PEECS and perforation in ESD is low and it would
4 not have been pragmatic to power a trial with these end points, given the sample size
5 required. Therefore, the number of “heat-treated bleeds” was used as a surrogate marker
6 and was designated the primary outcome measure. Purastat may have a role in
7 prevention of PEECS, although the existing literature has not assessed this. In this trial,
8 there were no cases of PEECS in either arm, so we may not draw any firm conclusions
9 from this. Nevertheless, a non-diathermic modality that allows the endoscopist to use
10 heat judiciously will continue to make ESD safer. This is relevant as the ESD expertise
11 in the West is currently not as good as in Japan and the risks are higher in the learning
12 curve phase [24,25].
13
14
15
16
17
18
19
20
21
22
23
24
25

26 This study also showed that the time taken to control IPB did not differ significantly
27 with the modality of treatment used (just over a minute in both). The transparent nature
28 of the gel made it possible for the endoscopist to accurately observe hemostasis as
29 visibility was maintained after application. There were no instances of early rebleeding
30 in either group.
31
32
33
34
35
36
37
38

39 The overall procedure time was also not prolonged in the interventional arm. Purastat
40 was not used for every bleed encountered as, in some bleeds, it was more pragmatic not
41 to exchange the endoscopic knife for the Purastat catheter, given the location of the
42 bleed and access. We felt that this model of tailoring the use of Purastat depending on
43 the type of bleed was the most practical way of using it and anticipate that future users
44 will adopt a similar strategy.
45
46
47
48
49
50
51
52

53 Our study also showed that only a small amount of Purastat was needed. It was feasible,
54 in many cases, for just a single 3-mL vial of hemostat to be used per ESD. We reported
55 on the technical aspects of gel application and found that there were no instances of
56 catheter blockage. The gel did not hamper dissection in the area of application as there
57
58
59
60

1
2
3 were no clinically perceptible differences in the conduction of current in this field. In
4
5 two cases, it was found to interfere with visibility, although it was possible to remove
6
7 the gel by vigorous flushing.
8
9

10 The overall delayed bleeding rate in this study was low (4%) and no difference was
11
12 noted between the groups. It is encouraging to note that there was no increase in delayed
13
14 bleeding in the interventional arm, which may permit us to infer that the hemostatic
15
16 efficacy of Purastat is sustained. In a previous study where Purastat was used
17
18 prophylactically following gastric ESD, the delayed bleeding rate was noted to be 2.2%
19
20 (no direct control group but this figure is lower than the average rate quoted in the
21
22 literature) [18].
23
24
25
26

27 Purastat may have beneficial effects on wound healing as noted in preclinical animal
28
29 studies [10]. The extracellular scaffold matrix promotes cell regeneration and
30
31 connective tissue repair, which may accelerate wound healing. It has been trialed for
32
33 use in the prevention of esophageal strictures after endoscopic resection in porcine
34
35 models, where the stricture rate in the interventional group was lower than the control
36
37 group (40% vs. 100%, $P = 0.2$) [26]. Only one other human clinical trial investigating
38
39 the wound healing effects of Purastat has been carried out, which demonstrated that
40
41 96% of cases reached the healing stage of post-gastric ESD ulceration after 1 week and
42
43 98% reached the scarring stage by 8 weeks [18]. In our study, almost 75% of the
44
45 patients followed up in the Purastat group achieved either complete wound healing or
46
47 scarring compared with 54% in the control group at 4 weeks. However, we noted that
48
49 there was no difference in the stages of wound healing in the esophageal ESD patients.
50
51 This may be because of the high dose proton pump inhibitor therapy and the timing of
52
53 follow-up in the esophageal lesions, where healing may be accelerated. In colorectal
54
55
56
57
58
59
60

1
2
3 ESD, 82% of patients in the Purastat group achieved complete healing or scarring
4 compared with 44% of controls.
5
6
7

8 There were several limitations to this study. Firstly, we did not include patients
9 undergoing gastric ESD (where the incidence of bleeding is higher), as the prevalence
10 of early gastric cancer in our population is low. However, Purastat may have a role to
11 play in reducing delayed bleeding in this group as two previous studies using Purastat
12 prophylactically post-gastric ESD have shown low delayed bleeding rates (0–2%),
13 although both lacked a control group [18,19]. A matched control study assessing the
14 hemostatic effects of Purastat following gastric endoscopic resection would increase
15 our understanding of its properties.
16
17
18
19
20
21
22
23
24
25

26 Secondly, given the paucity of data on IPB during ESD, we assumed that esophageal
27 and colonic ESD would have a similar incidence of bleeding and therefore did not
28 power the study to stratify recruitment and randomization according to lesion location.
29
30
31 Thirdly, as this was a pragmatic clinical trial designed to fit in with standard clinical
32 practice, we were not able to carry out additional follow-up procedures at weeks 1 and
33 2 post-ESD. This may have affected accurate assessment of the transition between the
34 stages of wound healing. It was also difficult to assess the impact of Purastat on the
35 incidence of PEECS, given the lack of data available and small sample size. We
36 acknowledge that Purastat will add to the cost of the procedure, but this study did not
37 assess its cost-effectiveness and impact on delayed bleeding as the focus was to
38 understand the basic principles of its efficacy and safety.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Despite the limitations, this study is the first randomized controlled trial to investigate
53 a novel hemostat for control of IPB during ESD. The primary end point of the trial was
54 met as Purastat does significantly reduce the need for heat treatment required for
55
56
57
58
59
60

1
2
3 hemostasis. This may improve the overall safety of ESD and highlights an emerging
4 role for this peptide as an adjunct to conventional hemostatic techniques during ESD.
5
6
7
8

9 **Acknowledgments**

10 The authors would like to thank the Wessex Clinical Research Network (National
11 Institute for Health Research) for their overall contribution with research infrastructure
12 to support the trial. We would also like to acknowledge 3D-Matrix Ltd. for the supply
13 of Purastat for the trial. There was no commercial involvement in the design,
14 implementation, analysis, and outcome of the results for this trial. Finally, we thank
15 Lisa Murray for her support with the protocol design and study set up.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Clinical trial**

32
33 Trial registry: [Clinical.Trials.gov](https://clinicaltrials.gov) | Registration number (trial ID): NCT02833558 |
34

35 Type of study: randomised controlled trial
36
37
38
39
40

41 *Competing interests:* The authors declare that they have no conflict of interest.
42
43
44

45 **References**

- 46 1 Enomoto S, Yahagi N, Fujishiro M et al. Novel endoscopic hemostasis technique
47 for use during endoscopic submucosal dissection. *Endoscopy* 2007; 39: E156
48
49
- 50 2 Hotta K, Yamaguchi Y, Saito Y et al. Current opinions for endoscopic submucosal
51 dissection for colorectal tumors from our experiences: Indications, technical
52 aspects and complications. *Dig Endosc* 2012; 24: 110–116
53
54
55
56
57
58
59
60

- 1
2
3 3 Yamashina T, Takeuchi Y, Uedo N et al. Features of electrocoagulation syndrome
4 after endoscopic submucosal dissection for colorectal neoplasm. *J Gastroenterol*
5
6 *Hepatol* 2016; 31: 615–620
7
8
9
- 10
11 4 Kataoka Y, Tsuji Y, Sakaguchi Y et al. Bleeding after endoscopic submucosal
12 dissection: Risk factors and preventive methods. *World J Gastroenterol* 2016; 22:
13
14 5927–5935
15
16
17
- 18
19 5 Nishizawa T, Suzuki H, Goto O et al. Effect of prophylactic clipping in colorectal
20 endoscopic resection: A meta-analysis of randomized controlled studies. *United*
21
22 *European Gastroenterol J* 2017; 5: 859–867
23
24
25
- 26
27 6 Park CH, Lee SK. Preventing and controlling bleeding in gastric endoscopic
28 submucosal dissection. *Clinical Endoscopy* 2013; 46: 456–462
29
30
31
- 32
33 7 Takizawa K, Oda I, Gotoda T et al. Routine coagulation of visible vessels may
34 prevent delayed bleeding after endoscopic submucosal dissection - An analysis of
35
36 risk factors. *Endoscopy* 2008; 40: 179–183
37
38
39
- 40
41 8 Mourad FH, Leong RW. Role of hemostatic powders in the management of lower
42 gastrointestinal bleeding: A review. *J Gastroenterol Hepatol* 2018; 33: 1445–1553
43
44
45
- 46
47 9 Huang R, Pan Y, Hui N et al. Polysaccharide hemostatic system for hemostasis
48 management in colorectal endoscopic mucosal resection. *Dig Endosc* 2014; 26:
49
50 63–68
51
52
- 53
54 10 Leung GKK, Wang YC, Wu W. Peptide nanofiber scaffold for brain tissue
55 reconstruction. *Methods Enzymol* 2012; 508: 177–190
56
57
58
59
60

- 11 Xu FF, Wang YC, Sun S et al. Comparison between self-assembling peptide nanofiber scaffold (SAPNS) and fibrin sealant in neurosurgical hemostasis. *Clin Transl Sci* 2015; 8: 490–494
- 12 Luo Z, Wang S, Zhang S. Fabrication of self-assembling d-form peptide nanofiber scaffold d-EAK16 for rapid hemostasis. *Biomaterials* 2011; 32: 2013–2020
- 13 Ye ZY, Zhang HY, Luo HL et al. Temperature and pH effects on biophysical and morphological properties of self-assembling peptide RADA16-1. *J Pept Sci* 2008; 14: 152–162
- 14 Song H, Zhang L, Zhao X. Hemostatic efficacy of biological self-assembling peptide nanofibers in a rat kidney model. *Macromol Biosci* 2010; 10: 33–39
- 15 Masuhara H, Fujii T, Watanabe Y et al. Novel infectious agent-free hemostatic material (TDM-621) in cardiovascular surgery. *Ann Thorac Cardiovasc Surg* 2012; 18: 444–451
- 16 Lee MF, Ma Z, Ananda A. A novel haemostatic agent based on self-assembling peptides in the setting of nasal endoscopic surgery, a case series. *Int J Surg Case Rep* 2017; 41: 461–464
- 17 Giritharan S, Salhiyyah K, Tsang G et al. Feasibility of a novel, synthetic, self-assembling peptide for suture-line haemostasis in cardiac surgery. *J Cardiothorac Surg* 2018; 13: 68
- 18 Uraoka T, Ochiai Y, Fujimoto A et al. A novel fully synthetic and self-assembled peptide solution for endoscopic submucosal dissection-induced ulcer in the stomach. *Gastrointest Endosc* 2016; 83: 1259–1264

- 1
2
3 19 Pioche M, Camus M, Rivory J et al. A self-assembling matrix-forming gel can be
4 easily and safely applied to prevent delayed bleeding after endoscopic resections.
5
6 Endosc Int Open 2016; 4: E415–E419
7
8
9
- 10
11 20 Yoshida M, Goto N, Kawaguchi M et al. Initial clinical trial of a novel hemostat,
12 TDM-621, in the endoscopic treatments of the gastric tumors. J Gastroenterol
13 Hepatol 2014; 29 Suppl 4: 77–79
14
15
16
17
18
- 19 21 Veitch AM, Vanbiervliet G, Gershlick AH et al. Endoscopy in patients on
20 antiplatelet or anticoagulant therapy, including Direct Oral anticoagulants: British
21 Society of Gastroenterology (BSG) and European Society of Gastrointestinal
22 endoscopy (ESGE) guidelines. Gut 2016; 65: 374–389
23
24
25
26
27
28
- 29 22 Subramaniam S, Kandiah K, Thayalasekaran S et al. Haemostasis and prevention
30 of bleeding related to ER: The role of a novel self-assembling peptide. United
31 European Gastroenterol J 2019; 7: 155–162
32
33
34
35
36
- 37 23 Sakita T, Fukutomi H. Endoscopic Diagnosis: Ulcer of Stomach and Duodenum.
38 Tokyo, Nankodo; 1971; 198–208
39
40
41
42
- 43 24. Fuccio L, Hassan C, Ponchon T et al. Clinical outcomes after endoscopic
44 submucosal dissection for colorectal neoplasia: a systematic review and meta-
45 analysis. Gastrointest Endosc 2017; 86: 74–86
46
47
48
49
- 50 25. Barret M, Lepilliez V, Coumaros D et al. The expansion of endoscopic
51 submucosal dissection in France: A prospective nationwide survey. United
52 European Gastroenterol J 2017; 5: 45–53
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26 Barret M, Bordacahar B, Beuvon F et al. Self-assembling peptide matrix for the prevention of esophageal stricture after endoscopic resection: a randomized controlled trial in a porcine model. *Dis Esophagus* 2017; 30: 1–7

1
2
3
4 **Fig. 1** Endoscopic views showing the application of Purastat for
5
6
7 intraprocedural bleeding.
8
9

10
11 **Fig. 2** The stages of wound healing of the resection base following
12
13
14
15 endoscopic submucosal dissection were categorized as: **a** healing
16
17
18 ulceration; **b** scarring; **c** complete healing.
19
20

21
22 **Fig. 3** Flow diagram of the study participants.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Baseline characteristics of the 101 patients enrolled in the study.

	Interventional arm (Purastat) n = 46	Control arm (diathermy) n = 45	<i>P</i> value
Age, mean (SD), years	68.6 (10.6)	71.5 (11.2)	0.22
Lesion size, mean (SD), mm	33.7 (12.1)	36.6 (13.6)	0.29
Sex, male : female, n	33 : 13	27 : 18	0.27
Co-morbidities present, n (%)	23 (50.0%)	17 (37.8%)	0.24
Cardiovascular disease	20 (43.5%)	15 (33.3%)	0.39
Ischemic heart disease	6 (13.0%)	7 (15.6%)	0.77
Hypertension	7 (15.2%)	5 (11.1%)	0.76
Atrial fibrillation	6 (13.0%)	4 (8.9%)	0.74
Valvular abnormalities	2 (4.3%)	0	0.50
Peripheral vascular disease	2 (4.3%)	2 (4.4%)	>0.99
Diabetes mellitus	2 (4.3%)	3 (6.7%)	0.68
Asthma/COPD	1 (2.2%)	1 (2.2%)	>0.99
Cerebrovascular accident/TIA	2 (4.3%)	2 (4.4%)	>0.99
Chronic liver disease	0	0	>0.99
On antithrombotic therapy, n (%)	19 (41.3%)	18 (40.0%)	0.90

Warfarin		5 (10.9%)	3 (6.7%)	0.71
Novel oral anticoagulant		1 (2.2%)	3 (6.7%)	0.36
Aspirin		7 (15.2%)	6 (13.3%)	>0.99
Clopidogrel		6 (13.0%)	6 (13.3%)	>0.99
En bloc resection rate, n (%)		35 (76.1%)	31 (68.9%)	0.44
Location, n (%)	Esophageal	28 (60.9%)	20 (44.4%)	0.12
	Colorectal	18 (39.1%)	25 (55.6%)	
Circumference, n (%)	<50%	32 (69.6%)	26 (57.8%)	0.24
	>50%	14 (30.4%)	19 (42.2%)	
Procedure type, n (%)	ESD	29 (63.0%)	26 (57.8%)	0.61
	Hybrid ESD	17 (37.0%)	19 (42.2%)	

SD, standard deviation; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; ESD, endoscopic submucosal dissection.

Table 2 Comparison of intraprocedural bleeding (IPB) and hemostat use between the two groups.

	Interventional arm (Purastat) n = 46	Control arm (Diathermy) n = 45	<i>P</i> value	
Total episodes of IPB, n	232	269	N/A	
Episodes of IPB that stopped spontaneously, n (%)	11 (4.7%)	7 (2.6%)	0.20	
Episodes of IPB that required hemostasis, n (%)	221 (95.3%)	262 (97.4%)	0.20	
Severity of bleeding, n (%)	Grade 1	105 (47.5%)	151 (57.6%)	0.03
	Grade 2	102 (46.2%)	101 (38.5%)	0.09
	Grade 3	14 (6.3%)	10 (3.8%)	0.21
Episodes of IPB treated with heat, n (%)*	109 (49.3%)	261 (99.6%)†	0.001	
Episodes of IPB treated with Purastat, n (%)‡	121 (54.8%)	0	N/A	
Successful hemostasis achieved with Purastat, n (%)	112/121 (92.6%)	N/A	N/A	

NA, not applicable.

1
2
3 * Includes nine bleeds treated with heat following unsuccessful hemostasis
4
5
6 with Purastat.
7

8
9 † One bleed required the use of endoscopic clips for safe hemostasis.
10

11
12 ‡ Includes the use of Purastat for hemostasis in nine bleeds following
13
14
15 unsuccessful diathermy.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3 Comparison of secondary outcomes between the two groups.

	Interventional arm (Purastat) n = 46	Control arm (diathermy) n = 45	<i>P</i> value
Procedure length, mean (SD), minutes	74.2 (48.7)	80.7 (56.6)	0.56
Time for hemostasis per bleed, mean (SD), seconds	70.0 (76.1)	77.6 (274.2)	0.14
Immediate/early rebleeding, n	0	0	
Delayed bleeding, n (%)	2 (4.3%)	2 (4.4%)	0.98
	Esophageal 1	Esophageal 1	
	Colonic 1	Colonic 1	
Perforation, n (%)	1 (2.2%)	0	0.32

SD, standard deviation.

Table 4 Comparison of wound healing between the two groups.

Wound healing categories	Interventional arm (Purastat) n = 43	Control arm (diathermy) n = 44	<i>P</i> value
Complete healing, n (%)	21 (48.8%)	11 (25.0%)	0.02
Scarring, n (%)	11 (25.6%)	13 (29.5%)	0.69
Healing ulceration, n (%)	11 (25.6%)	20 (45.5%)	0.05

Table 5 Subgroup analysis of wound healing according to lesion location.

	Esophageal (n = 45)			Colorectal (n = 42)		
	Purastat (n = 26)	Control (n = 19)	<i>P</i> value	Purastat (n = 17)	Control (n = 25)	<i>P</i> value
Complete healing	14 (53.8%)	7 (36.8%)	0.26	7 (41.2%)	4 (16.0%)	0.07
Scarring	4 (15.4%)	6 (31.6%)	0.20	7 (41.2%)	7 (28.0%)	0.38
Healing ulceration	8 (30.8%)	6 (31.6%)	0.96	3 (17.6%)	14 (56.0%)	0.01

In brief

A novel self-assembling peptide was shown in this single-center randomized controlled trial, involving 101 patients, to reduce the need for thermal therapy for intraprocedural hemostasis during esophageal or colonic ESD, with no difference in procedural time, time for hemostasis, or delayed bleeding rate. Further studies are needed to investigate the cost-effectiveness of this peptide.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Application of Purastat® for intraprocedural bleeding

352x125mm (144 x 144 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Stages of Wound Healing of ESD Resection Base
(a) Healing Ulceration; (b) Scarring; (c) Complete Healing

152x352mm (144 x 144 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

